Codexis Publishes FY2023 Sustainability Disclosures
August 15 2024 - 4:05PM
Codexis, Inc. (NASDAQ: CDXS), a leading enzyme engineering company,
today announced the publication of its inaugural sustainability
disclosures detailing the Company’s environmental, social, and
governance (“ESG”) performance for the fiscal year ended December
31, 2023. The disclosures are aligned with guidance provided by the
International Financial Reporting Standards’ (“IFRS”)
Sustainability Accounting Standards Board (“SASB”). This marks an
important step in Codexis’ sustainability journey and bolsters its
efforts to provide stakeholders with important disclosures in a
clear and standardized manner.
As Codexis continues its growth as a partner of
choice for sustainable drug manufacturing, the Company looks
forward to building upon today's disclosures and making meaningful
advancements in its sustainability performance and future
reporting. To learn more about Codexis’ sustainability program or
obtain a copy of Codexis’ FY2023 SASB index, please visit the
Company’s website.
About CodexisCodexis is a
leading enzyme engineering company leveraging its proprietary
CodeEvolver® technology platform to discover, develop and
enhance novel, high-performance enzymes and other classes of
proteins. Codexis enzymes solve for real-world challenges
associated with small molecule pharmaceuticals manufacturing and
nucleic acid synthesis. The Company is currently developing its
proprietary ECO Synthesis™ manufacturing platform to enable the
scaled manufacture of RNAi therapeutics through an enzymatic route.
Codexis’ unique enzymes can drive improvements such as higher
yields, reduced energy usage and waste generation, improved
efficiency in manufacturing and greater sensitivity in genomic and
diagnostic applications. For more information,
visit www.codexis.com.
Forward-Looking StatementsThis
press release includes “forward-looking statements,” as the term is
defined under the federal securities laws. Forward-looking
statements are those statements that are not statements of
historical fact. Forward-looking statements can be identified by
forward-looking words such as “expects,” “anticipates,” “intends,”
“plans,” “may,” “will,” “believes,” “seeks,” “estimates,” and
similar expressions. These statements are based on management’s
current opinions, expectations, beliefs, plans, objectives,
assumptions or projections regarding future events or future
results, including, but not limited to, our ESG commitments,
strategies and initiatives; our business plans and strategy; our
products, services and solutions; and our stakeholder engagement
efforts. These forward-looking statements are only predictions, not
historical fact, and involve certain risks and uncertainties, as
well as assumptions. Actual results, levels of activity,
performance, achievements and events could differ materially from
those stated, anticipated or implied by such forward-looking
statements. While Codexis believes that its assumptions are
reasonable, it is very difficult to predict the impact of known
factors and it is impossible to anticipate all factors that could
affect actual results. There are many risks and uncertainties that
could cause actual results to differ materially from
forward-looking statements herein including, most prominently, the
risks discussed under the heading “Risk Factors” in the Company’s
Annual Report on Form 10-K filed with the Securities and Exchange
Commission (“SEC”) on February 28, 2024 and in the Company’s
Quarterly Report on Form 10-Q filed with the SEC on August 8, 2024,
including under the caption “Risk Factors,” and in Codexis’ other
periodic reports filed with the SEC. Codexis expressly disclaims
any intent or obligation to update these forward-looking
statements, except as required by law.
For More Information
Investor ContactCarrie McKim(336) 608-9706ir@codexis.com
Media ContactLauren Musto(650) 421-8205media@codexis.com
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Nov 2024 to Dec 2024
Codexis (NASDAQ:CDXS)
Historical Stock Chart
From Dec 2023 to Dec 2024